Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study. IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication.
Lead Product(s): IM-250
Therapeutic Area: Infections and Infectious Diseases Product Name: IM-250
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Life Sciences Partners
Deal Size: $23.7 million Upfront Cash: Undisclosed
Deal Type: Series A financing June 07, 2021